7 Hills Pharma

• Upendra Marathi

  President

Sources: reporter.nih.gov

• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  Phase 1/2, Recruiting, 126 people, Apr 12, 2024

Sources: clinicaltrials.gov

• National Institute of Allergy and Infectious Diseases

  R44, 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination, R44AI176894, $953K, 2023–2026, Mar 27, 2024

Sources: reporter.nih.gov